DC-SIGN Increases the Affinity of HIV-1 Envelope Glycoprotein Interaction with CD4

Karolijn Hijazi1, YuFei Wang1, Carlo Scala1, Simon Jeffs2, Colin Longstaff3, Daniel Stieh4, Beth Haggarty5, Guido Vanham6,7,8, Dominique Schols9, Jan Balzarini9, Ian M. Jones10, James Hoxie5, Robin Shattock4, Charles G. Kelly1

1 King's College London, Dental Institute, Oral Immunology, Tower Wing, Guy's Hospital, London, United Kingdom, 2 Jefferson Trust Research Laboratories, Wright-Fleming Institute, Division of Medicine, Faculty of Medicine, Imperial College, London, United Kingdom, 3 Biotherapeutics Section, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom, 4 Centre for Infection, Department of Cellular and Molecular Medicine, St George's, University of London, London, United Kingdom, 5 Penn Center for AIDS Research, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, 6 Virology Unit, Division of Microbiology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium, 7 Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium, 8 Faculty of Medicine and Pharmacy Free University of Brussels, Brussels, Belgium, 9 Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium, 10 School of Biological Sciences, University of Reading, Reading, United Kingdom

Abstract

Mannose-binding C-type lectin receptors, expressed on Langerhans cells and subepithelial dendritic cells (DCs) of cervico-vaginal tissues, play an important role in HIV-1 capture and subsequent dissemination to lymph nodes. DC-SIGN has been implicated in both productive infection of DCs and the DC-mediated trans infection of CD4+ T cells that occurs in the absence of replication. However, the molecular events that underlie this efficient transmission have not been fully defined. In this study, we have examined the effect of the extracellular domains of DC-SIGN and Langerin on the stability of the interaction of the HIV-1 envelope glycoprotein with CD4+ and also on replication in permissive cells. Surface plasmon resonance analysis showed that DC-SIGN increases the binding affinity of trimeric gp140 envelope glycoproteins to CD4. In contrast, Langerin had no effect on the stability of the gp140:CD4 complex. In vitro infection experiments to compare DC-SIGN enhancement of CD4-dependent and CD4-independent strains demonstrated significantly lower enhancement of the CD4-independent strain. In addition DC-SIGN increased the relative rate of infection of the CD4-dependent strain but had no effect on the CD4-independent strain. DC-SIGN binding to the HIV envelope protein effectively increases exposure of the CD4 binding site, which in turn contributes to enhancement of infection.

Introduction

Dendritic cell (DC) subsets [1–3] as well as Langerhans cells (LCs) [4–6] in genital mucosal tissue may play a key role in transmission of human immunodeficiency virus type 1 (HIV-1) to CD4+ T cells. While CD4+ T cells form the founder populations of infected cells at the portal of entry [5,7], DCs and LCs contribute to viral dissemination to lymphoid tissues and enhance amplification of viral replication in CD4+ T cells at mucosal sites [8]. DCs and LCs bind HIV and transfer virus to permissive CD4+ T cells in a process termed trans infection that does not require HIV replication in DCs or LCs [4,9]. In addition, immature DCs and LCs express low levels of cell surface CD4 and CCR5 and are susceptible to infection with HIV [10–12]. Although replicative infection in DCs and LCs is much less efficient than in CD4+ T cells and macrophages [5,13,14], infected DCs and LCs can efficiently release de novo synthesized virus particles to CD4+ T cells at the points of cell contact termed virological synapses [5,15–17]. Thus DC-mediated transmission of virus involves two different mechanisms that can be distinguished temporally [17]. Within 24 hours of exposure to HIV, DCs transmit either surface bound virus or internalised virus in trans (in the absence of productive replication) [18]. Beyond this time-point, immature DCs that have been infected transmit progeny rather than input virus to permissive target cells that express CD4 and chemokine receptors [16,17]. Mannose-binding C-type lectin receptors expressed on the surface of LCs and subepithelial DCs of cervico-vaginal tissues bind the highly glycosylated HIV envelope protein and capture HIV [9,11,19], although other unidentified receptors may also bind HIV [20]. In particular, the C-type lectin DC-SIGN (DC specific ICAM-3-grabbing nonintegrin) has been identified as a
cell surface receptor on immature DCs that binds HIV and mediates transfer of virus to CD4+ permissive T cells [9,15,18,21,22]. DC-SIGN binding to HIV results in internalisation of virus to a non-endolysosomal compartment [17,18]. From this compartment, internalised virus moves rapidly to synapses formed by infected DCs and CD4+ T cells, however, within 24 hours HIV in this compartment is degraded concomitant with a decline in transfer of infectious input virus [17].

DC-SIGN binding to HIV may also enhance DC infection directly and so contribute to the second longer-term mechanism of DC-mediated infection that involves transfer of progeny virus to CD4+ T cells [17,23]. Co-expression of DC-SIGN with CD4 and CCR5 in transfected cell lines or in T cell lines resulted in modest (two- to five-fold) increases in infection with HIV-1 although the relative enhancement was increased in cell lines that expressed lower levels of CCR5 [22,24]. DC-SIGN binding to HIV-1 anchors the virus and may provide an increased local concentration of virus at the DC surface that facilitates interaction with CD4 and co-receptor [22,24].

Not all mannos-binding C-type lectin receptors enhance infection either in trans or when expressed in cis with CD4 and co-receptor. In contrast to DC-SIGN, the LC-specific lectin Langerin mediates a protective effect since binding of HIV results in internalisation into Birbeck granules and rapid degradation [25]. Thus binding of HIV at the cell surface is not sufficient per se to enhance infection.

In this study, we have investigated the interaction between DC-SIGN or Langerin with gp140 (soluble, trimeric ectodomain of HIV envelope glycoprotein) to determine whether factors other than concentration at the cell surface also contribute to cis enhancement of infection. Surface plasmon resonance assays demonstrate that binding of DC-SIGN, but not Langerin, to HIV gp140 considerably increases the affinity of binding of gp140 to CD4. Enhancement of infection in vitro of permissive cells that express DC-SIGN was greater for the CD4-dependent HIV-1 IIIB strain than for the CD4-independent strain HIV-1 IIIBx [26]. This is consistent with the proposal that DC-SIGN may promote infection of immature dendritic cells by both concentrating virus at the cell surface and promoting binding to CD4.

**Materials and Methods**

**Reagents and cells**

The human anti-gp41 Mab 5F3 [27] was a kind gift of D. Katinger (Pölymum GmbH, Vienna, Austria). The mouse anti-DC-SIGN Mab 120507 was from R&D Systems (Abingdon, Oxon, UK). CHO-expressed soluble CD4, Mab b12 [28] and Mab 447-52D [29,30] were obtained through the Centralised Facility for AIDS Reagents (CFAR), National Institute for Biological Standards and Controls (NIBSC, Potters Bar, Herts, United Kingdom) and were donated by Progenics Pharmaceuticals, Inc., USA, D. P. Burton and S. Zolla-Pazner, respectively. The lectin HHA was prepared as described [31]. T-20 (Fuzeon) was from Roche, Welwyn Garden City, UK. Mannan was purchased from Sigma-Aldrich (Poole, UK), Recombinant E. coli DnaJ was provided by E. McGowan (King’s College London, London, UK).

**Cells**

PM1 cells (CFAR, NIBSC, donated by Paolo Lusso) [32], THP-1_ATCC and THP-1_ATCC/DC-SIGN cells (referred to as THP-1 and THP-1DC-SIGN hereafter) (NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH, Germantown, MD, USA, original source L. Wu and V. N. KewalRamani) [33] were grown in RPMI 1640 medium supplemented with 10% foetal calf serum, 100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine. 293T/17 cells (ATCC #CRL-11268, Manassas, VA, USA), used for expression of recombinant gp140, were maintained in Dulbecco’s Modified Eagles Medium (DMEM) (Invitrogen, Paisley, UK) supplemented with 10% foetal calf serum. Cells were grown in an environment enriched with CO₂ (5%) at 37°C and passaged every 2–3 days or at approximately 80–90% confluence and the number of passages did not exceed 5. Immature monocyte-derived DCs were generated as previously described [21].

**Virus stocks**

HIV-1 clade B strains 92FR Bx08 (BX08) [34,35] and IIIB [36] were obtained through the CFAR, NIBSC and were donated by V. Polonis and R. Gallo, respectively. IIIBx, the CD4-independent variant of IIIB, was derived as previously described [37]. Viruses were propagated in peripheral blood mononuclear cells (PBMCs) isolated from buffy coats (National Blood Transfusion Service, London, UK) using a Ficol-Hypaque density gradient. Prior to infection PBMCs were activated with phytohaemagglutinin (PHA; 0.5 μg/ml; Sigma) and IL-2 (20 U/ml; Sigma). 50% tissue culture infective dose (TCID₅₀) values of cell free viral stocks were determined in PM1 or THP-1 cells as previously described [38]. Infectivity was estimated by measurement of p24 antigen release in the supernatant by enzyme-linked immunosorbent assay (HIV-1 p24 Antigen ELISA Kit, Zetaprintex Corp, Buffalo, NY, USA) according to the manufacturer’s instructions.

**Expression and purification of DC-SIGN**

Complementary DNA of immature monocyte-derived dendritic cells was used as template to generate the DNA fragment encoding the entire extracellular domain of DC-SIGN (residues 70-404, GenBank accession number NP_066978) by PCR with primers 5’-GTCTTCGAGATGGAACACATTCCAGGACCGGATCT-3’ (sense) and 5’-TCGGATCCCTACGCAGGAGGGGGTT-TGCGGTT-3’ (antisense). The amplified sequence, digested with XhoI and BamHI was inserted in pET15b (Novagen, EMD Chemicals, Gibbstown, NJ, USA) and cloned in E. coli TOP10 (Invitrogen). Cloned fragments were confirmed by DNA sequencing (Advanced Biotechnology Centre, Imperial College London, London, UK) and compared with GenBank (accession number NM_021155). For expression, E. coli strain BL21/D3 (Strategene, La Jolla, CA, USA) was transformed with recombinant plasmid. Protein expression and refolding was performed as described [39] with minor modifications. Inclusion bodies (from 11 bacterial culture) were recovered by centrifugation at 10,000 × g for 20 min at 4°C, and solubilized in 8 ml of 100 mM Tris-HCl, pH 8.0 containing 6 M urea (solubilizing buffer) supplemented with 0.01% 2-mercaptoethanol, by gentle rotation for 16 h at 4°C. The mixture was centrifuged at 20,000 × g for 30 min at 4°C and soluble recombinant protein was isolated by Ni²⁺ affinity chromatography. Bound material (recovered by elution with 200 mM imidazole in solubilizing buffer) was dialyzed against 21 of 100 mM Tris-HCl, pH 8.0, 0.01% 2-mercaptoethanol, 10 mM CaCl₂, 4 M urea then successively against the same buffer with 2 M urea and no urea. Final dialysis was against 100 mM Tris-HCl, pH 8.0, 10 mM CaCl₂. After dialysis, insoluble precipitate was removed by centrifugation at 100,000 × g for 30 min at 4°C and refolded DC-SIGN present in the soluble fraction was purified by D-mannose affinity chromatography as previously described [40]. Fractions were analyzed by SDS-PAGE and protein concentrations were determined by densitometric analysis using the GeneSnap software (Syngene, Cambridge, UK).
The identity of the protein was confirmed by liquid chromatography tandem mass spectrometry (LC MS/MS) analysis (MRC Clinical Sciences Centre, Imperial College London, London, UK).

**Expression and purification of Langerin**

The sequence encoding the full extracellular domain of Langerin (residues 56–328, Genbank accession number CAB62403) was synthesized and cloned (Epoch Biolabs, Missouri City, TX, USA) in pET15b (Novagen). E. coli strain BL21/DE3 was transformed for expression. Inclusion bodies were recovered and protein purification and refolding was carried out as previously described [41]. The identity of the protein was confirmed by LC MS/MS analysis (MRC Clinical Sciences Centre, Imperial College London).

**Size exclusion chromatography**

Refolded proteins (approximately 50 μg) were resolved by size exclusion chromatography on two tandemly connected Superdex 200 3.2/30 PG columns with the AKTAbasic system (GE Healthcare, Uppsala, Sweden) in 100 mM Tris-HCl, pH 7.9, 0.15 M NaCl with flow rate of 0.05 ml/min at room temperature. Absorbance was monitored at 280 nm, and fractions were analyzed by SDS-PAGE. Molecular mass was estimated by comparing the elution positions on the chromatogram to those of marker proteins injected under identical conditions (apoferritin, 450,000; transferrin, 80,000; bovine serum albumin, 67,000; ovalbumin, 400,000; α-amylase, 200,000; alcohol dehydrogenase, 150,000; trypsin, 80,000; bovine serum albumin, 67,000; ovalbumin, 45,000; β-lactoglobulin dimer, 36,000; carbonic anhydrase, 30,000; myoglobin, 18,000).

**Expression and purification of gp140**

Gene fragments encoding BX08 gp140 (residues 31–663) and IIB gp140 (residues 31–665) were amplified from pSFV BX08 wtgp160 (kind gift of Ralf Wagner, University of Regensburg, Germany), harbouring the gp160 sequence derived from BX08, and the molecular clone pHBI10 (CFAR, NIBSC), respectively, modified and inserted into the pEE14/tpa vector (Lonza Biologics plc, Slough, UK) under control of the human tissue plasminogen activator signal peptide as previously described [42]. The identity of the protein was confirmed by liquid chromatography and protein purification and refolding was carried out as previously described [41]. The identity of the protein was confirmed by LC MS/MS analysis (MRC Clinical Sciences Centre, Imperial College London).

For protein immobilization by direct amine coupling to the surface of CM5 sensorchips (GE Healthcare), samples were dissolved in 10 mM Na acetate (pH 4.0). For binding studies, HBS-P buffer (10 mM HEPES [pH 7.4], 0.15 M NaCl, 0.005% vol/vol surfactant P20; GE Healthcare) supplemented with 10 mM CaCl₂, was used. Flow rate was 20 μl/min. Equilibrium dissociation constants (K₅ₐ) as well as association (kₐ) and dissociation constant (k₅ₐ) rates were calculated using the BIAevaluation software 4.1 (GE Healthcare). Curves were fitted to the model which gave the best fit as judged by the lowest Chi² value and best distribution of deviation from the calculated fit.

**Determination of gp140 direct binding to DC-SIGN and Langerin.**

Gp140 at 0.5 μg/ml was immobilized on the sensorchip surface of flow cell 2 by direct amine coupling (560 and 620 resonance units (RU) for BX08 or IIB, respectively). Flow cell 1 served as reference. Binding of fluid phase DC-SIGN (50–600 nM) or Langerin (25–200 nM) was then determined. The sensorchip surface was regenerated with 10 mM EDTA.

**Effect of soluble DC-SIGN and Langerin on stability of gp140 interaction with CD4.**

Mab 5F3 (2 μg/ml) was immobilized by direct amine coupling on both flow cell 1 and flow cell 2 (approximately 6000 and 5500 RU, respectively) and gp140 (100 nM) was injected over flow cell 2. DC-SIGN or Langerin (both at 50 nM) were then injected over both flow cells followed by injection of gp140 ligands (CD4, Mab b12, or Mab 447-52D) at varying concentrations. Reproducibility of binding of gp140, DC-SIGN or Langerin binding was verified by repeated injections. Difference sensograms of CD4 binding were obtained after subtracting dissociation of 5F3:gp140 or 5F3:gp140:DC-SIGN/Langerin complexes. Because of the very low dissociation rate of the gp140:CD4 complex in the presence of DC-SIGN, rate constants could not be calculated for this binding. To allow comparison between binding ≥ DC-SIGN, values for the half-life (t₁/₂) of the complexes were calculated using the formula t₁/₂ = ln 2/k₅ₐ (t₁/₂ = 0.693/k₅ₐ).

No binding of DC-SIGN or CD4 to immobilised 5F3 was evident in the control flow cell. In addition, in separate experiments where CD4 was injected over immobilised DC-SIGN, no binding of CD4 was detected.

**Flow cytometry**

To assess binding of soluble DC-SIGN to PM1 cells, serial dilutions of protein (5–350,000 pM) were incubated with PM1 cells (0.25 × 10⁶) for 30 min at 4°C. Cells were washed three times with cold PBS and incubated with 5 μl of anti-DC-SIGN Mab (10 μg/ml, clone 120507) for 30 min followed by a further 30 min incubation with FITC-conjugated goat anti-mouse IgG (Dako, Cambridgeshire, UK). An isotype control murine antibody of irrelevant specificity was used as negative control. Binding of HHA to PM1 cells was assessed by incubation of PM1 cells with serial dilutions of FITC-conjugated HHA (EY Laboratories, San Mateo, CA, USA) for 30 min at 4°C. After incubation, cells were extensively washed with PBS, FITC-conjugated Lotus tetragonolobus lectin (Vectorlabs, Peterborough, UK) was used as negative control. For some experiments, mannan (100 μg/ml) was added to DC-SIGN or HHA before incubation with cells. The cells were then analysed by a BD FACSCanto II flow cytometer using the FACSDiva software (Becton Dickinson, Oxford, UK) and data analysis was performed using the WinMDI 2.9 software.

**Purification of viral particles and virus binding assays**

Viral particles were inactivated using aldrithiol-2 as previously described [45]. Inactivated virus was concentrated by centrifuging on a 17–25% sucrose cushion at 35,000 rpm in a SW55Ti centrifuge for 16 h as previously described [46]. Pellets were resuspended in PBS supplemented with 10 mM EDTA and 1% BSA. CD45 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) were added at a concentration of 10 μl/μg p24 and incubated with mixing for 4 h. Virus was then concentrated again by centrifugation on a 25% sucrose cushion at 55,000 rpm for 1 h. Samples
were then resuspended in degassed PBS with 1 mM EDTA for binding experiments. Binding activity of virions to soluble DC-SIGN was assessed on a RapiID4 acoustic biosensor (TTP Labtech). Soluble DC-SIGN and BSA were covalently bound on the experimental and control flow cells respectively by direct amine coupling. Serial dilutions of purified or unpurified virus (34–250 nM) determined by p24 ELISA and normalized assuming 2500 gag proteins per virion [46] were prepared and allowed to bind to the surface for 3 min, followed by 5–10 min of dissociation. For experiments with unpurified virus, cell culture supernatant of uninfected cells was used as negative control. Surfaces were regenerated with 100 mM glycine-HCl, pH 2.5. Data were fitted to the Langmuir kinetic model.

Cell viability assays
Cell viability was assessed by the in situ reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT assay) [47]. PM1 cells (0.2×10⁶) were seeded in 96-well plates and exposed to recombinant proteins for 72 h at 37°C. Cells were washed with PBS and treated with MTT (0.5 mg/ml; Sigma) in RPMI for 3 h. Cells were then solubilized overnight with 20% SDS in H₂O:DMF (1:1) and the absorbance determined at 570 nm, with reference at 630 nm. Viability was estimated by comparison with viable cells exposed to medium alone and assays were performed in triplicate.

Infections
For αi-enhancement assays, infection of the permiscive cell line THP-1 was compared with that of THP-1-DC-SIGN. THP-1 and THP-1-DC-SIGN cells were infected with HIV IIIB or HIV IIIBx at MOI of 1–4×10⁻⁴. Two hours post-infection unbound virus was washed off with three volumes of RPMI. After 10 days, p24 levels were measured by HIV p24 antigen ELISA. For assessment of viral binding, THP-1 and THP-1-DC-SIGN cells were incubated with HIV IIIB or HIV IIIBx at p24 concentrations of 0–100 ng/ml. After 2 h cells were lysed with 1% Triton-X and p24 levels were measured by ELISA. For infection assays with soluble lectins, serial dilutions (in triplicate) of test protein (0–40,000 pM) were pre-incubated with HIV-1 (BX08 or IIIB) at 10⁻⁴ MOI (as determined in PM1 cells) for 30 min at 37°C and subsequently added to PM1 cells (0.4×10⁶) in 96-well, round bottom, tissue culture plates. For some experiments, mannan (10 µg/ml) was added to the mixture of DC-SIGN and virus. Cultures were incubated at 37°C for 10 days. Viral replication was measured by p24 ELISA and defined as %p24 protein release in the absence of test compound, which was defined as 100% and corresponded to 68–100 pg/ml. 50% inhibitory concentrations (IC₅₀) were estimated by linear regression analysis using GraphPad Prism 5 software (San Diego, CA). For all experiments heat-inactivated virus (1 h at 56°C) was used as background correction. Each condition was assayed in a minimum of three independent experiments.

Spinoculation and fusion kinetics assays
To measure the rate of virus-cell fusion we used spinoculation to provide synchronous infection [48,49]. Viruses (IIIB or IIIBx) at 3×10⁻⁴ MOI were mixed with THP-1 and THP-1-DC-SIGN cells and centrifuged at 1,200 × g, 4°C for 3 hours. Cultures were then washed with fresh medium and warmed to 37°C prior to addition of T-20 or Mab b12 at 10 µg/ml at the following time points: 0, 15, 30, 60, 120, 180, 240 and 360 min. Levels of p24 in the supernatant were assayed after 4 days and relative infectivity values were defined as %p24 protein released in the absence of inhibitor for each virus and cell type, which was defined as 100%.

Heat-inactivated virus (1 h at 56°C) was used as background correction. Each condition was assayed in triplicate in 4 independent experiments.

Statistics
Analyses were performed using GraphPad Prism 5. Normal distribution of data was demonstrated using the D’Agostino-Pearson normality test. Comparison of two data sets and estimation of two-tailed P values was carried out using unpaired t test with Welch’s correction.

Results
Expression and characterization of recombinant DC-SIGN and Langerin
Recombinant polypeptides comprising the extracellular domains of DC-SIGN and Langerin, respectively, were expressed in E. coli, refolded and purified by affinity chromatography on Ni²⁺ and mannose resins sequentially. Identity of the polypeptides was confirmed by peptide sequence analysis. Refolded DC-SIGN bound to Mab 120507 with K_D of approximately 2×10⁻⁹ M as determined by surface plasmon resonance (data not shown) in agreement with previous findings [50]. The oligomeric state of DC-SIGN and Langerin was determined by size exclusion chromatography. Both proteins eluted as two well-resolved major peaks corresponding to the molecular mass of the monomeric and tetrameric forms of DC-SIGN (Fig. 1A) [50], and the monomeric and trimeric forms of Langerin (Fig. 1B). Some non-lectin components were also evident in a minor peak (labeled 3) in the Langerin preparation. The relative distribution of the higher and the lower molecular mass forms was 3.3:1 for DC-SIGN and 3.7:1 for Langerin. When fractions from the higher molecular mass peak were re-chromatographed, the proteins redistributed with approximately the same proportion of higher and lower molecular mass forms (data not shown). In these preparations, the tetrameric form of DC-SIGN and the trimeric form of Langerin predominated in monomer:oligomer equilibria.

Recombinant DC-SIGN and Langerin bind HIV-1 gp140. Binding of recombinant DC-SIGN and Langerin to soluble trimeric gp140 envelope glycoproteins was measured by surface plasmon resonance. For these experiments, gp140 from HIV-1 BX08 (R5 clade B) or IIIB (X4 clade B) was immobilized directly on the sensorchip surface and binding of fluid phase DC-SIGN or Langerin was determined over a range of concentrations (50–600 nM for DC-SIGN, 25–200 nM for Langerin). Superimposed sensograms are shown in Fig. 1C–F. Data could not be fitted to a 1:1 Langmuir binding model using the BLAevaluation software but, for both DC-SIGN and Langerin, data fitted to a heterogeneous analyte model in which it is assumed that both lectin preparations include oligomeric and monomeric forms in the proportions indicated by the gel filtration analyses. The equilibrium dissociation constants (K_D) calculated for the tetrameric form of DC-SIGN were approximately two orders of magnitude lower than those calculated for the monomer (Fig. 1C and 1D). The difference can be attributed to the lower dissociation constant (K_D) estimated for the tetramer compared with that of the monomer. In this model, tetrameric DC-SIGN is the dominant form of the lectin that binds to gp140. The K_D values for tetrameric DC-SIGN binding to gp140 (BX08) and gp140 (IIIB) were approximately 0.062 µM and 0.063 µM, respectively, in agreement with values (0.003–0.061 µM) reported previously for DC-SIGN binding to gp120 from 4 different strains of HIV-1 [50]. The trimeric form of Langerin also bound to gp140 with higher affinity than the monomer again attributed to the slower dissociation of the trimer. Trimeric Langerin bound with higher
affinity than DC-SIGN to gp140 with KD2 values of approximately 0.024 µM (BX08) and 0.011 µM (IIIB) (Fig. 1E and 1F).

DC-SIGN, but not Langerin, increases the stability of gp140:CD4 complex

To investigate whether formation of the complex of DC-SIGN with gp140 altered the affinity of interaction between gp140 and CD4 and to compare the effect of DC-SIGN with that of Langerin, a capture assay was used. The human anti-gp41 Mab 5F3 was immobilized on both experimental and reference flow cells followed by injection of gp140 over the surface of the experimental flow cell only. Mab 5F3 bound with high affinity to both preparations of gp140 with KD values of approximately 3×10^{-11} M (Fig. 2A and 2B). As shown schematically in Fig. 2I,
DC-SIGN or Langerin was then injected (over both flow cells) followed by CD4. Using this system, we compared CD4 binding to gp140 (BX08 and IIIB) complexed with DC-SIGN or Langerin to that of gp140 alone. Superimposed sensograms of fluid phase CD4 binding to gp140 (BX08) in the absence of DC-SIGN (with subtraction of gp140 dissociation from the capture antibody) are shown in Fig. 2C. Again, the data could not be fitted to the 1:1 Langmuir binding model but were fitted to a two-step linked reaction binding model. The apparent Kd, 2.4 nM, is in agreement with previously reported values for CD4 interaction with gp120 from BH10 [51] and JRFL [52]. When DC-SIGN was injected and allowed to complex with gp140 (BX08) before injection of CD4, the kinetics of interaction were considerably altered. The superimposed sensograms (with subtraction of dissociation of the gp140:DC-SIGN:5F3 complex) (Fig. 2E), indicate a large decrease in the rate of dissociation of the complex. An accurate estimation of the dissociation rate was not possible and therefore other kinetic constants could not be calculated. We therefore calculated the half-life (t1/2) of the respective gp140:CD4 complexes to compare their stability. For the gp140:CD4 complex formed in the absence of DC-SIGN, t1/2 was approximately 15 min whereas for the complex formed in the presence of DC-SIGN t1/2 was >190 h (assuming a Kd value of 10^-6 M^-1 as the limit of detection using surface plasmon resonance), consistent with an essentially irreversible interaction in this system. Although Langerin bound to gp140 (BX08) with higher affinity compared to DC-SIGN no significant effect on CD4 binding was observed when gp140 was complexed with Langerin (Fig. 2G), with t1/2 of 16 min for the Langerin:gp140:CD4 complex. DC-SIGN also enhanced stability of the gp140 (IIIB) complex with CD4 (Fig. 2D and 2F). A small decrease in the dissociation rate of the gp140:CD4 complex was also evident in the presence of langerin (Fig. 2H). CD4 (without prior addition of gp140) did not bind to immobilized DC-SIGN or Langerin (data not shown).

**Effect of cis expression of DC-SIGN on kinetics of cell fusion**

Using the same system, we then compared the effect of DC-SIGN on the kinetics of infection with IIIB and IIIBx strains. For these experiments, HIV was adsorbed to cells by spinoculation at low temperature to promote synchronous infection [48,49]. Cultures were warmed to 37°C and the fusion inhibitor T-20 was added to cultures at defined time intervals and at a completely inhibitory concentration. The rate at which virus became resistant to T-20 inhibition provides a measure of the rate of completion of HIV fusion. There was no detectable infection when T-20 was added to cultures up to 30 minutes after warming (Fig. 4A) indicating the time required in this system for formation of the fusion complex and subsequent adoption of the helix bundle conformation. At the next time point (60 minutes) infection of both THP-1 and THP-1DC-SIGN cells with both IIIB and IIIBx strains was evident. As before, levels of infection were higher in THP-1DC-SIGN cells (Fig. 4A). A plot of relative infection against time (Fig. 4B) revealed significant differences in the rate of infection of the two strains of HIV. Despite the difference in level of infection (Fig. 4A), the relative rate of infection by HIV IIIBx was similar for both THP-1 and THP-1DC-SIGN cells whereas that of infection by IIIB was slower in THP-1 cells compared with THP-1DC-SIGN cells (Fig. 4B). The more efficient capture of virus by DC-SIGN leads to higher levels of infection but, in addition, for a wholly CD4-dependent strain the relative rate of infection is increased. We suggest that the increased rate is a consequence of DC-SIGN stabilising the gp120:CD4 complex. Addition of Mab b12 [28] at any time after spinoculation had no effect, consistent with the finding that virus binds to CD4 during spinoculation [48].

**Effect of soluble DC-SIGN on HIV-1 infection in vitro**

The data reported above indicate that *cis* expression of DC-SIGN enhances infection with HIV-1 both by concentrating virus at the cell surface and by stabilising binding of gp120 to CD4. We compared the effects of soluble DC-SIGN or soluble Langerin on HIV infection in *vitro* as a means of addressing whether the increased stability of the CD4:gp120 complex contributes to DC-SIGN enhancement of *trans* infection. In a previous study [28], inhibition of infection of T cells was evident when soluble DC-SIGN was added to virus in *vitro* at concentrations in the range of 2–200 nM. Furthermore, in separate assays, virus capture was reduced by approximately 50% following addition of soluble DC-SIGN at a concentration of approximately 2 nM. We therefore carried out a titration of DC-SIGN that included sub-nanomolar...
concentrations. DC-SIGN, Langerin or the plant lectin HHA was added to virus particles to addition of PM1 cells and p24 levels were determined after culture for 10 days. HHA has previously been identified as a microbicide that binds to HIV gp120 [54] [55]. At concentrations of DC-SIGN <1 nM, significantly increased p24 levels were evident in the supernatants of both BX08 and IIB strains compared to the control (no treatment) with maximum enhancement of 3.6-fold and 15.3-fold, respectively (Fig. 5A and 5C). At higher concentrations, DC-SIGN inhibited replication, as previously described [29], with IC50 of 2.5 nM (BX08) and 4 nM (IIB). In contrast, Langerin, and HHA had no enhancing effect at sub-nanomolar concentrations but inhibited infection with both HIV-1 strains in a dose-dependent manner with IC50 values in the range of 1.6–5 nM (Fig. 5B and 5D), as previously reported for HHA [1]. Both enhancing and inhibitory activities of DC-SIGN were abrogated in the presence of mannan (Fig. 5E) confirming that the effects are mediated by carbohydrate binding. DnaJ (included as a control recombinant polypeptide of irrelevant specificity) showed no significant effect. None of the compounds showed toxicity in the MTT dye reduction assay (Fig. 5F).

Both (enhancing) DC-SIGN and (non-enhancing) HHA lectins bound to PM1 cells as observed by FACS analyses (data not shown). At the highest concentration tested (300 nM) for each lectin, the level of binding determined as mean fluorescence intensity (MFI) of HHA to PM1 cells was higher (MFI = 22.15, 89.4%) than that observed for DC-SIGN (MFI = 8.89, 14.7%). We cannot therefore exclude the possibility that enhancement of infection was due to tetravalent DC-SIGN acting as a bridge to bind virus to the PM1 cell surface. However, the observation that tetravalent HHA binds more strongly to PM1 cells suggests that bridging per se is not sufficient to enhance infection. We suggest that at low concentrations, soluble DC-SIGN but not Langerin (or HHA) stabilises interaction of gp120 on the virus surface with CD4 to enhance infection. At higher concentrations, binding of more than one molecule of soluble DC-SIGN to gp120 [53] may sterically hinder binding to cell surface DC-SIGN.

**DC-SIGN increases binding affinity of gp140 to anti-CD4-binding site neutralizing Mab b12, but not to an anti-V3 Mab**

The enhanced binding of CD4 to gp140 induced by DC-SIGN may result from increased availability of the CD4 binding site. We tested the effect of DC-SIGN on gp140 interaction with Mab b12 directed against the CD4 binding site and of Mab 447–52D directed against the V3 loop of gp120 [29]. As described above, gp140 was non-covalently bound on the experimental flow cell by capture using immobilised Mab 5F3. Binding of Mabs b12 or 447–52D at various concentrations was then measured in the presence or absence of DC-SIGN. Fig. 6A shows superimposed sensograms of fluid phase Mab b12 binding to gp140 (BX08) alone. The data fitted the two-step dissociation model of binding with apparent $K_d$ 7.9 x 10^{-9} M in good agreement with previous findings [56]. When DC-SIGN was bound to gp140 by prior injection, dissociation of Mab b12 from the DC-SIGN:gp140 complex was considerably reduced (Fig. 6B). The rate of dissociation (and therefore kinetic constants) could not be determined (as shown in Fig. 2 for CD4 binding to the same complex). Binding of Mab 447–52D to gp140 in the presence or absence of DC-SIGN was also measured in this system. DC-SIGN had no significant effect on interaction of Mab 447–52D with gp140 (Fig. 6C–D).

**Discussion**

In this study, we have demonstrated that DC-SIGN-mediated enhancement of infection with HIV-1 is the result not only of increasing the concentration of virus at the cell surface as suggested previously [24] but also of the increased affinity of the DC-SIGN:gp120 complex for CD4. The C-type lectins DC-SIGN and Langerin both bind to HIV-1 envelope protein but with different outcomes. Whereas binding of HIV to DC-SIGN may enhance infection, binding of HIV to Langerin leads to internalisation and degradation of HIV, as outlined above. To compare directly the effect of DC-SIGN and Langerin binding to HIV-1 envelope protein, we developed a surface plasmon resonance-based binding assay in which gp140 was immobilised indirectly on the sensorchips by antibody, and binding of soluble CD4 could be reproducibly measured with or without prior binding of soluble DC-SIGN or soluble Langerin. The findings revealed qualitative differences between binding of the two C-type lectins. In this system, binding of DC-SIGN to immobilised gp140 resulted in a large increase in the affinity with which the complex bound to CD4 compared with binding of gp140 alone. The increase in affinity was mainly due to a decrease in the dissociation rate of the trivalent DC-SIGN:gp140:CD4 complex compared with gp140:CD4. In contrast, Langerin had little or no effect on the dissociation of CD4 from the complex with gp140. These findings confirm those reported previously where DC-SIGN binding to gp120 was shown to enhance binding of the complex to CD4 using an ELISA-based system [57].

For the binding studies reported here, gp140 produced in human 293T cells was used so that the glycosylation pattern more closely resembles that of native envelope proteins of HIV-1 particles. Previous studies of HIV-1 gp120 produced in insect or mammalian cells demonstrated marked differences in binding to CD4 and some antibodies of the differently glycosylated forms [58]. Significant differences in glycosylation between gp120 produced in 293T cells or in a T cell line (Jurkat) have also been described [59] with 293T cell-derived material having less high mannose and more complex N-linked glycans than the Jurkat-derived material. However, in contrast to gp120, gp140 produced in 293T cells shows a much simpler, predominantly oligomannose profile of glycans that correlates well with the glycan profiles of envelope proteins purified from functional virus particles produced in 293T cells or human blood peripheral mononuclear cells [60].
Figure 3. Binding properties and infectivity of CD4-dependent (IIIb) and CD4-independent (IIIbx) strains of HIV-1. (A, B) Superimposed sensorgrams (acoustic biosensor) of fluid phase IIIb (A) and IIIbx (B) viral particles (34–250 nM determined by p24 ELISA and normalized assuming 2500 gag proteins per virion) binding to immobilized DC-SIGN. Kd values are indicated. (C, D) Binding of IIIb and IIIbx to THP-1 (C) and THP-1 DC-SIGN (D) cells. Virus was incubated with cells for 2 h and after washing and cell lysis, p24 levels were estimated. Experiments were repeated twice, each point in triplicate. (E) Infection (10^{-4} MOI) by IIIb and IIIbx of THP-1 DC-SIGN and THP-1 cells represented as concentration of p24 antigen released in the supernatant. (F) Data from (E) as fold-increase in infection relative to THP-1. IIIbx infection level was significantly lower than IIIb (**, P = 0.001). Experiments were repeated twice (5 replicates).

doi:10.1371/journal.pone.0028307.g003
We also used preparations of DC-SIGN and Langerin that were mostly tetrameric or trimeric, respectively, reflecting the oligomeric structure of the cell surface forms of these lectins [41,61] and in which binding was predominantly by the oligomeric forms.

Although both DC-SIGN and Langerin bind to oligomannose structures on the HIV envelope protein, significant differences in the binding properties of DC-SIGN and Langerin revealed by crystallographic studies [62,63] may account for the observation that DC-SIGN but not Langerin increases the affinity of gp140 for CD4. DC-SIGN binds preferentially to the outer trimannose branch point within N-linked high mannose glycans [62] whereas Langerin binds preferentially to linear oligomannoses [64,65]. The carbohydrate recognition domain of Langerin includes a novel second carbohydrate binding site in addition to the site conserved in C-type lectins [66]. Modelling studies suggest that N-linked high mannose glycans may bind to Langerin through a terminal mannose residue of another branch at the alternative site [67]. In addition, the 3 carbohydrate recognition domains within the Langerin trimer are fixed in position by multiple interactions with the neck region [64] and likely to bind to a preformed target site. In contrast, the carbohydrate recognition domains of tetrameric DC-SIGN are more flexible [63] and may therefore bind to a wider range of glycans.

To determine whether the increased affinity of the DC-SIGN:envelope bimolecular complex binding to CD4 contributed to DC-SIGN mediated cis enhancement of infection, as suggested previously [57], we used a cellular model of infection [18,24] that compares infection of DC-SIGN transfected and non-transfected THP-1 cells. Although the effect of DC-SIGN was to increase infection by both CD4-dependent and CD4-independent strains of HIV, the level of enhancement was consistently lower for the CD4-independent strain. In the same model, we also determined kinetics of infection for both HIV strains in the two cell types. For this we used spinoculation at low temperature to produce synchronous infection of cells [48,49] and then measured the rate at which inoculated HIV became resistant to the fusion inhibitor T-20, corresponding to the time required for adoption of the six-helix bundle conformation of gp41 [68]. In contrast to IIIBx where the relative rate of infection is not affected by DC-SIGN, the relative rate of infection of IIIB was increased by cis expression of DC-SIGN such that it was similar to that of the CD4-independent strain. Thus the increased stability of gp120:CD4 interaction conferred by DC-SIGN contributes in turn to faster formation of the six-helix bundle. Binding analyses combined with structural determination [69] have indicated rapidly reversible binding of CD4 to gp120 in which CD4 binds to a site that is constitutively exposed but then readily dissociates. The complex may be stabilised by multiple copies of CD4 at the surface of T cells. In contrast, the low levels of cell surface CD4 in DCs [11] may not provide the increased avidity required to stabilise the initial gp120:CD4 complexes. Data from this study shows that DC-SIGN may significantly contribute to cis infection by decreasing the dissociation of CD4, thereby promoting formation of the complex with gp120 leading to more rapid co-receptor binding and fusion. This may be a significant factor in infection of DCs. The IIIBx strain retains CD4 binding activity showing enhanced fusion activity when CD4 and CXCR4 were coexpressed on target cells for fusion assays [37] and we cannot rule out such activity contributing to infection in the assays performed in this study. The observation that the relative rate of infection with IIIBx is not affected by cis expression of DC-SIGN, however, suggests that DC-SIGN enhances infection of this strain only by increasing the level of virus binding to the cell surface. It is striking that DC-SIGN increases the relative rate of infection with the parental IIIB strain so that it resembles that of IIIBx indicating that the increased stability of the DC-SIGN:Env:CD4 complex may lead to more rapid co-receptor engagement.

The system used here of comparing CD4-dependent and CD4-independent virus strains in the presence or absence of DC-SIGN to distinguish between the DC-SIGN-mediated effects of increasing binding of virus to the cell surface and increasing the stability of the gp120:CD4 complex cannot be applied to trans enhancement of infection. We therefore investigated the effect of inoculating virus in the presence of soluble DC-SIGN in comparison with the effect of adding soluble Langerin or HHA. At low concentrations, only DC-SIGN mediated enhancement of infection whereas at higher concentrations all lectins were inhibitory. We suggest that inhibition is due to excess bound lectin sterically blocking the site for binding CD4 whereas, at low concentrations of DC-SIGN, DC-SIGN:envelope complexes on
the virus surface bind more avidly to CD4 on the target cells. The multivalent lectins used in this experiment recognise carbohydrate structures on the host cell and could enhance infection by acting as a bridge to target HIV to the cell surface. We demonstrated, however, that although both HHA and DC-SIGN bound to the PM1 cells, used as permissive targets, only DC-SIGN enhanced infection suggesting that the specificity of lectin interaction but not bridging contributes to enhancement.

We also showed that DC-SIGN increases the affinity of binding of the broadly neutralising monoclonal antibody b12 which recognises an epitope that largely overlaps with the CD4 binding site of gp120 [69] consistent with the proposal that DC-SIGN exposes the CD4 binding site. Similarly, binding of the mannose-rich glycan-specific lectin, griffithsin, to gp120 has been shown to enhance binding of b12 and modestly enhances binding of a soluble form of CD4 [70]. The N-linked glycan at position 386 contributed partly to griffithsin-mediated enhancement of binding. This glycan was also identified as a component of the optimal DC-SIGN binding site on gp120 [53]. Molecular modelling suggests that this glycan shields the

Figure 5. DC-SIGN, but not Langerin, enhances replication in PM1 cells by HIV-1. Levels of p24 are represented as %p24 production in the control wells, which was defined as 100%. Each condition was assayed in triplicate in two independent experiments. (A, B) Effect of soluble DC-SIGN (A), Langerin and HHA (B) on PM1 cells infection by HIV-1 (BX08). (C, D) Effect of soluble DC-SIGN (C), Langerin and HHA (D) on PM1 infection by HIV-1 (IIIIB). DnaJ (Δ), used as control protein, and mannan alone (×) showed no significant effect. (E) Effect of soluble DC-SIGN at increasing concentrations on PM1 cells infection by HIV-1 (BX08) in the presence (Δ) and absence (×) of mannan at 10 μg/ml. (F) Effect of DC-SIGN and Langerin on viability of PM1 cells assessed by MTT dye reduction assays.

doi:10.1371/journal.pone.0028307.g005
CD4 binding site and enhanced macrophage tropism was observed in a HIV Env variant that lacked the glycan at position 386 [71]. Thus we suggest that DC-SIGN binding to the N-linked glycan at position 386 may contribute to exposure of the CD4 binding site and DC-SIGN-mediated enhancement of infection. This glycan is not essential for DC-SIGN-mediated virus capture since it is one of five N-linked glycans lacking in gp120 of the IIIBx strain [37].

Binding of HIV to DC-SIGN on the surface of DCs may have a number of different outcomes. In the absence of productive infection, virus may be transmitted in trans to permissive target cells. In addition, by concentrating virus at the DC cell surface, DC-SIGN increases the likelihood of interaction in cis with DC cell surface CD4 and co-receptor as suggested previously [22,24] leading to infection in cis. In parallel, DC-SIGN also mediates internalisation and degradation of HIV in endosomes [16,17]. Recognition of released HIV-1 genomic RNA by TLR8 and binding of HIV-1 envelope protein to DC-SIGN provide two signals that are essential for initiation of transcription and production of full length viral transcripts [72], thus also enhancing infection in cis. In this study, we demonstrate a further effect of DC-SIGN that contributes to enhanced infection either in cis or in trans, namely significantly increasing the half-life of the envelope glycoprotein:CD4 complex which in turn promotes co-receptor engagement.

**Author Contributions**

Conceived and designed the experiments: KH YW CK GV RS DStieh. Performed the experiments: KH YW CS DStieh. Analyzed the data: KH YW CL CK DStieh. Contributed reagents/materials/analysis tools: GV DSchohs JB BH JH SJ IMJ. Wrote the paper: KH CK.
References

1. Cameron PU, Freudenhal PS, Barker JM, Gezelter S, Inaba K, et al. (1992) Dendritic cells exposed to human immunodeficiency virus type 1 transmit a vigorous cytopathic effect to CD4+ T cells. J Virol 66: 257–303.

2. Pope M, Haase AT (2005) Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 11: 847–852.

3. Shattock RJ, Moore JP (2005) Inhibiting sexual transmission of HIV-1 infection. Nat Rev Immunol 5: 23–34.

4. Faehndrich KM, Barry SM, Ayehunie S, Lamore S, Klausner R, et al. (2007) Activated CD4+ dendritic cells mediate transmission with human immunodeficiency virus. J Virol 81: 6858–6608.

5. Hladik F, Sahakianthorn P, Balabaner L, Lenz G, Flakios M, et al. (2007) Initial events in establishing vaginal entry and infection by human immunodeficiency virus type 1. Immunity 26: 257–270.

6. Kawamura T, Kurtz SE, Blauvelt A, Shimada S (2005) The role of Langerhans cells in the sexual transmission of HIV. J Dermatol Sci 40: 147–153.

7. Hladik F, McClain MJ (2006) Setting the stage: host invasion by HIV. Nat Rev Immunol 8: 447–457.

8. Kelle BF, Este JD (2011) Barriers to mucosal transmission of immunodeficiency viruses. Blood 118: 939–946.

9. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, et al. (2000) DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100: 567–579.

10. Kawamura T, Golden FG, Sugaya M, McNamara BT, Bosrl DL, et al. (2003) R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci U S A 100: 8401–8406.

11. Turville SG, Cameron PU, Handley A, Lin G, Pohlmann S, et al. (2002) Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol 3: 975–983.

12. Zaitseva M, Blauvelt A, Lee S, Lapham CK, Klaus-Kovun V, et al. (1997) Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat Med 3: 1369–1375.

13. Granelli-Piperno A, Delgado E, Finkel V, Paxton W, Steinman RM (1997) Immature dendritic cells selectively replicate macrophage-tropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells. J Virol 71: 2733–2737.

14. Pope M, Gezelter S, Gallo N, Hoffmann I, Steinman RM (1995) Low levels of infection in cutaneous dendritic cells promote extensive viral replication upon binding to memory CD4+ T cells. J Exp Med 182: 2043–2056.

15. McDonald D, Wu L, Boksi SM, KewalRamanuni VN, Unutmaz D, et al. (2003) Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 300: 1295–1297.

16. Nobile C, Petit C, Moris A, Skrabal K, Abastado JP, et al. (2005) Covert human immunodeficiency virus infection in cutaneous dendritic cells promote extensive viral replication upon binding to memory CD4+ T cells. J Virol 79: 5386–5399.

17. Turville SG, Santos JJ, Frank I, Cameron PU, Wilkinson J, et al. (2004) Blockade of cell type-dependent retention and transmission of HIV-1 by DC-SIGN. J Exp Med 199: 1065–1075.

18. Trumpfheller C, Park CG, Finke J, Steinman RM, Granelli-Piperno A (2003) DC-SIGN, L-SIGN, and DC-SIGNR are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem 278: 20358–20366.

19. Moog C, Sperdelchner C, Fleury H, Heshmati F, Saragosti S, et al. (1997) Neutralization of primary isolates of HIV-1 isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD44 and to interfere with cell-line-tropic HIV-1. J Virol 69: 3712–3720.

20. Duerk PA, Hsu Y-J, Falletta C, Markham PD, Poskanzer DS, et al. (1995) Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol 69: 3712–3720.

21. Wu L, Martin TD, Carrington M, KewalRamanuni VN (2004) Raji B cells, misidentified as THP-1 cells, stimulate DC-SIGN-mediated HIV transmission. Virology 318: 17–23.

22. Brown BK, Darden DM, Tovanabutra S, Obarber T, Frost J, et al. (2005) Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J Virol 79: 6019–6101.

23. Moog C, Sperdelchner C, Fleury H, Heshmati F, Saragosti S, et al. (1997) Neutralization of primary human immunodeficiency virus type 1 isolates: a study of parameters implicated in neutralization in vitro. AIDS Res Hum Retroviruses 13: 19–27.

24. Popovic M, Flomenberg N, Volkman DJ, Mann D, Fauci AS, et al. (1984) Alteration of T-cell functions by infection with HTLV-I or HTLV-II. Science 226: 45–67.

25. LaBranche CC, Hoffman TL, Romano J, Haggarty BS, Edwards TG, et al. (1999) Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. J Virol 73: 10310–10319.

26. Van Herwege Y, Penne L, Vereecken C, Fransen K, van der Groen G, et al. (2002) Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: a possible in vitro model for postexposure prophylaxis of sexual HIV transmission. AIDS Res Hum Retroviruses 18: 1091–1102.

27. Mitchell DA, Fadden AJ, Drickamer K (2001) A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J Biol Chem 276: 20939–20945.

28. Zloty P, Lortat-Jack H, de Lacroix de LA, Staropoli I, Fourg S, et al. (2003) DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem 278: 20536–20546.

29. Stambach NS, Taylor ME (2003) Characterization of carbohydrate recognition by langerin, a C-type lectin of Langerhan cells. Glycobiology 13: 401–410.

30. Jeffs SA, Gröpp S, Kebble B, Crane D, Bolgiano B, et al. (2004) Expression and characterization of recombinant mucin type E helix-loop-glycopolysaccharides derived from primary isolates of HIV-1. Vaccine 22: 1032–1046.

31. Jeffs SA (2007) Production of recombinant viral vaccine antigens. In: Stacey G, Davis J, eds. Medicines from Animal Cell Culture John Wiley & Sons Ltd, London, pp 59–77.

32. Thomas M, Lee JI, Ge Q, Zhang C, Chen J, et al. (2005) Full deacylation of polyethyleneimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc Natl Acad Sci U S A 102: 3679–3684.

33. Rossio JL, Esiri MT, Suryanarayana K, Schneider DK, Bus JW, et al. (1998) Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 72: 7992–8001.

34. Chertova E, Chertov O, Coren LV, Roser JD, Trubey CM, et al. (2006) Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol 80: 9030–9052.

35. Hummers TM (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55–63.

36. O’Doherty U, Swingdij W, Malina MH (2000) Human immunodeficiency virus type 1: spinoculation enhances infection through virus binding. J Virol 74: 10074–10080.

37. Platt EF, Durnin JP, Kabat D (2005) Kinetic factors control efficiencies of cell entry, efficiencies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus type 1. Virology 328: 457–466.

38. Snyder GA, Ford J, Toraño-Parizi A, Anthos JA, Schuck P, et al. (2005) Characterization of DC-SIGN/R interaction with human immunodeficiency virus type 1 gp120 and ICAM molecules favors the receptor’s role as an antigen—capturing receptor rather than an adhesion receptor. J Virol 79: 4508–4508.

39. Mysza DG, Sweet RW, Henley P, Brigham-Burke M, Kwong PD, et al. (2000) Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci U S A 97: 9026–9031.
52. Zhang W, Goddard AP, Wyatt R, Sodroski J, Chakravorty I (2001) Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4. Biochemistry 40: 1662–1670.

53. Hong PW, Nguyen S, Young S, Su SV, Lee B (2007) Identification of the Optimal DC-SIGN Binding Site on Human Immunodeficiency Virus Type 1 gp120. J Virol 81: 8325–8336.

54. Astoul GH, Peumans WJ, Van Damme EJ, Rougé P (2000) Accessibility of the high-mannose glycans of glycoprotein gp120 from human immunodeficiency virus type 1 probed by in vitro interaction with mannose-binding lectins. Biochem Biophys Res Commun 274: 455–460. 10.1006/bbrc.2000.3166 [doi];S0006291X00931668 [pii].

55. Balzarini J, Hatse S, Vermeire K, Princen K, Aquaro S, et al. (2004) Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob Agents Chemother 48: 3835–3870.

56. Thali M, Moore JP, Furman C, Charles M, Ho DD, et al. (1993) Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 67: 3978–3988.

57. Lekkerkerker AN, Ludwig IS, van Vliet SJ, van Kooyk Y, Geijtenbeek TB (2004) Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120. Virology 329: 465–476. S0042-6822(04)00579-3 [pii];10.1016/j.virol.2004.08.028 [doi].

58. Kong L, Sheppard NC, Stewart-Jones GB, Robson CL, Chen H, et al. (2004) Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity. J Mol Biol 403: 131–147.

59. Raska M, Takahashi K, Czernekova L, Zachova K, Hall S, et al. (2010) Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J Biol Chem 285: 20860–20869.

60. Bernhard OK, Lai J, Wilkinson J, Sheil MM, Cunningham AL (2004) Proteomic analysis of DC-SIGN on dendritic cells requires tetramers for ligand binding but no association with CD4. J Biol Chem 279: 51828–51835.

61. Feinberg H, Mitchell DA, Drickamer K, Weis WI (2001) Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR. Science 294: 2163–2166.

62. Feinberg H, Guo Y, Mitchell DA, Drickamer K, Weis WI (2005) Extended neck regions stabilize tetramers of the receptors DC-SIGN and DC-SIGNR. J Biol Chem 280: 1327–1333.

63. Feinberg H, Poeschland AS, Taylor ME, Weis WI (2010) Trimeric structure of langerin. J Biol Chem 285: 13285–13293.

64. Chatwell L, Holla A, Kauer BB, Skerra A (2008) The carbohydrate recognition domain of Langerin reveals high structural similarity with the one of DC-SIGN but an additional, calcium-independent sugar-binding site. Mol Immunol 45: 1981–1994.

65. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732–737.

66. Alexandre KB, Gray ES, Pantophlet R, Moore PL, McMahon JB, et al. (2011) Binding of the mannose-specific lectin, griffithsin, to HIV-1 gp120 exposes the CD4-binding site. J Virol.